Cellebrite DI Stock-Based Compensation Growth & History (CLBT)
Cellebrite DI's stock-based compensation was $44.9M for fiscal 2025.
View full Cellebrite DI company overviewCellebrite DI annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $44.9M | $14.3M | +46.83% |
| 2024 | 2024-12-31 | $30.6M | $11.6M | +60.94% |
| 2023 | 2023-12-31 | $19.0M | $5.3M | +38.59% |
| 2022 | 2022-12-31 | $13.7M | $7.2M | +111.54% |
| 2021 | 2021-12-31 | $6.5M | −$791,000 | −10.88% |
| 2020 | 2020-12-31 | $7.3M | −$5.5M | −43.01% |
| 2019 | 2019-12-31 | $12.8M | — | — |
Cellebrite DI quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $15.2M | $6.4M | +73.09% |
| Q1 2026 | 2026-03-31 | $14.4M | $5.6M | +63.88% |
| Q4 2025 | 2025-12-31 | $12.0M | — | — |
| Q3 2025 | 2025-09-30 | $15.3M | — | — |
| Q2 2025 | 2025-06-30 | $8.8M | — | — |
| Q1 2025 | 2025-03-31 | $8.8M | — | — |
Cellebrite DI stock-based compensation trends
Over the last five fiscal years, Cellebrite DI's stock-based compensation increased from $7.3M to $44.9M, a change of $37.6M. The latest reported quarter, Q2 2026, shows $15.2M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cellebrite DI source filings ↗